Protein could lead to better TB vaccine

The current vaccine for tuberculosis uses a bovine version of the disease to protect humans who've contracted the illness. It provides some protection but is not entirely effective. However, researchers from the National Heart and Lung Institute at Imperial College London say they've identified a protein that elicits a stronger immune response in those with TB. The protein, called EspC, could be used to provide more better immunity than the currently available vaccine. Report

Suggested Articles

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

AstraZeneca scored a $1 billion contribution from the United States for development, production and delivery of its potential COVID-19 vaccine.

AZ is among the companies leading the COVID-19 vaccine race, and after agreeing first to supply the U.K., it's now in talks for delivery worldwide.